that cannot be classified into any of the above types. Regarding Type V, we classified 0-IIc-like advanced type tumors into Type V tumors. 3 Therefore, in the present study, we used the term "Type V" to indicate unclassifiable tumors plus 0-IIc-like advanced type tumors ( Figure 1A ).
The relationship between macroscopic features and prognosis was determined more than 30 years ago. 4 However, multivariate analyses sometimes prevented independent significance of macroscopic features for the prognosis of gastric cancer patients, [5] [6] [7] whereas pathological factors such as tumor depth or lymph node metastasis as well as distant metastasis were almost always selected as independent prognostic factors. Therefore, gastric cancer staging which should accurately predict the prognosis of patients is defined by tumor depth, lymph node metastasis, and distant metastasis.
In Japan, therapeutic strategy for gastric cancer is different were published, postoperative chemotherapy is usually given for pathological stage II/III gastric cancer. 8, 9 However, the prognosis of patients with pathological stage III gastric cancer is so unsatisfactory, even after S-1 adjuvant chemotherapy, that a more potent chemotherapeutic regimen is needed for such patients.
In contrast, performance status of gastrectomized patients is so poor that a potent regimen such as triplet chemotherapy cannot be given. Thus, in practice or in clinical trials, preoperative adjuvant chemotherapy has recently been conducted in Japan. [10] [11] [12] Therefore, prognostic factors independent of pathological stage have been helpful for determining the therapeutic strategy, and age and macroscopic features were finally proven to be the most potent independent prognostic factors among preoperatively obtainable ones in advanced gastric cancer requiring gastrectomy. 13 However, elderly status results in mandatory and compromised therapeutic strategies in terms of lymph node dissection extent, indication for adjuvant chemotherapy, and execution of potent and effective chemotherapy after recurrences, so prognosis of elderly gastric cancer patients rather reflects therapeutic intensity than tumor aggressiveness from a prognostic point of view. It may not represent aggressive intrinsic characteristics of the tumor.
In contrast, macroscopic features have sometimes been reported to be a prognostic factor independent of stage, 3, [13] [14] [15] [16] and this clinical factor is likely to represent tumor aggressiveness. Macroscopic features long denied as a prognostic factor have re-emerged as crucial for determining therapeutic strategy.
Macroscopic features are clearly correlated with histological differentiation, and the differential histology harboring specific macroscopic features has been subcategorized by the molecular features of the whole genome, 17 suggesting that, in gastric cancer, macroscopic classification of gastric cancer might be essential for precision medicine linked to specific high-efficacy molecular targeted therapy. Importantly, Japan Clinical Oncology Group (JCOG) considers giant Type III and Type IV tumors as such dismal prognostic phenotypes that it has defined them as high-risk gastric cancer, and promising new therapeutic strategies are rigorously being developed for optimized treatments in clinical trials to improve survival outcomes. 10, 18 In the present article, we reviewed the re-emerging clinical relevance of the macroscopic appearance of gastric cancer in the context of rigorous investigation of prognosis and debate the best optimized treatment strategy in the era of precision medicine. 
| MacroscopicType0cancer
Because of the widespread use of endoscopic screening, over half of Japanese patients who undergo gastric resection for gastric cancer have early stage, that is, macroscopic Type 0 cancer. 19 Recurrence rate of patients with cStage I gastric cancer undergoing laparoscopic gastrectomy has been reported to be 0%-2.5% [21] [22] [23] ( Figure 2C ). Even when cT1 tumor turned out to be pT2 or more advanced after surgical resection, the overall survival rate was reported to be as high as 90%. 24 Survival outcomes of cT1 gastric cancer are so good that we should concentrate on how to improve quality of life (QOL) of patients undergoing surgical resection by carrying out function-preserving surgery such as proximal gastrectomy, 25, 26 pylorus-preserving gastrectomy, [27] [28] [29] as well as local resection, while securing the same oncological outcomes. For this purpose, sentinel node navigation surgery will be promising for next-generation therapy in cT1 gastric cancer at present requiring gastrectomy.
30,31
Features of early-stage gastric cancer without lymph node metastasis have been well clarified. [32] [33] [34] Tumors with very rare incidence of lymphatic metastasis should be resected endoscopically.
Japanese gastric cancer treatment guidelines 2014 indicate endoscopic resection for the following tumors rather than gastrectomy:
differentiated-type adenocarcinoma without ulcerative findings
] of which depth of invasion is diagnosed as cT1a and diameter is ≤2 cm. In contrast, endoscopic treatment of tumors diagnosed as cT1a and (i) of differentiated-type, UL(−), but >2 cm in diameter; or (ii) of differentiated-type, UL(+), and ≤3 cm in diameter; or (iii) of undifferentiated-type, UL(−), and ≤2 cm in diameter has been considered as investigational. 35 In the JCOG0607 study, however, endoscopic submucosal dissection (ESD) for cT1a and (i) of differentiated-type, UL(−), but >2 cm in diameter; or (ii) of differentiated-type, UL(+), and ≤3 cm in diameter achieved a 5-year overall survival rate of 97.0%, which was higher than the expected threshold of 86.1%. 36 Therefore, instead of gastrectomy, indication 
| MacroscopicTypeI,II,andVcancers
In advanced (cT2/pT2 or deeper) gastric cancer, macroscopic appearance was proven to be a simple and important indicator of prognosis 3 (Table 1 ). Macroscopic features of types I, II, and V were a better prognostic indicator than other types independent of tumor stage, and they could be designated as conventional advanced gastric cancer differentially from Type III/IV advanced gastric cancer (Figure 2A,B) . In fact, in our experience, prognosis of patients with macroscopic features of types I, II, and V was slightly better than in those with S-1 adjuvant chemotherapy in the ACTS-GC trial with a 5-year overall survival rate of 76.6% and 71.7%, respectively. 3, 9 All patients with types I, II, and V in our experience received adjuvant chemotherapy with S-1. Currently, D2 gastrectomy with postoperative S-1 is the standard treatment strategy for this type of gastric cancer. More recently, the JACCRO GC-07 trial showed that adjuvant S-1 plus docetaxel is superior to adjuvant S-1 monotherapy after D2 gastrectomy for pStage III gastric cancer in terms of survival outcomes. 40 When this treatment strategy of adjuvant S-1 plus docetaxel after D2 gastrectomy is adopted, prognosis of patients with macroscopic features of types I, II, and V will improve further. 17 In contrast, CIN gastric cancer is tightly associated with p53 mutation. 17 We identified cancer-specific methylated genes which are in the p53 tumor suppressor pathway [43] [44] [45] and ablated the p53 pathway in tumor tissues in an epigenetic way together with wild-type p53. The identified genes were PGP9.5, NMDAR2B, and CCNA1 which were exclusively methylated in primary tumors with no p53 mutation. Gastric cancer patients were classified into three categories based on the p53 mutation status as well as on the DNA methylation status of PGP9.5, NMDAR2B and CCNA1. These three categories were p53 mutant, p53
wild type with super-high methylation (SHM) of the above three p53
pathway genes (p53 WT/SHM), and p53 wild type without SHM (p53 WT without SHM). We further designated the p53 mutant plus the p53 WT/SHM groups as the p53 aberration group, and p53 WT without SHM was designated as the p53 no-aberration group. Although no difference of prognosis between diffuse-type and intestinal-type gastric cancer was found in the p53 no-aberration group, intestinaltype gastric cancer showed poorer prognosis than diffuse-type cancer in the p53 aberration group 46 ( Figure 3A ).
From such a prognostic point of view, CIN gastric cancer, characterized by p53 mutation, is the most concerning problem regarding the prognosis of intestinal-type gastric cancer. Intriguingly, a recent report showed that p53 mutation is highly correlated with liver metastasis in gastric cancer, 47 so CIN gastric cancer deserves attention to target gain of function of the p53 mutation in intestinal-type gastric cancer beyond the standard treatments. 48 
TA B L E 1 Previous reports concerning survival outcomes by each macroscopic type

| MacroscopictypesIIIandIVcancer
Type III is the most frequent macroscopic type of curable advanced gastric cancer ( Figure 1B) , whereas Type IV is the most disastrous type of gastric cancer from a prognostic point of view. We previously analyzed approximately 5000 patients with gastric cancer who underwent gastrectomy and concluded that Type IV gastric cancer accounted for 5.5% of the patients and was associated with the most dismal prognosis with a 5-year overall survival rate of 16%.
14 However, Type III gastric cancer accounted for 17% of patients with a 5-year overall survival rate of 34% in total cases, 13 and 59% when peritoneal lavage cytology test was negative (CY0). 49 In Type III gastric cancer, positive peritoneal lavage cytology test (CY1) was proven to be the strongest independent poor prognostic factor with a hazard ratio of 2.37, while tumor size was also a potent prognostic factor among those with CY0. 49 Allowing for these prognostic features, in JCOG Stomach Cancer Study Group, giant Type III and Type IV gastric cancer is believed to be a high-risk gastric cancer among resect- Figure 3B ). Dismal prognosis of gastric cancer of Type III/IV macroscopic appearance is largely explained by treatment failure of peritoneal dissemination, and neoadjuvant chemotherapy may be promising to improve prognosis of such high-risk gastric cancer, because perioperative chemotherapy of epirubicin/cisplatin/5-FU (ECF) can improve the dismal prognosis of gastric cancer in the western world. 50 Recently, chemoradiotherapy after preoperative chemotherapy and surgery for resectable gastric cancer did not improve overall survival compared with perioperative chemotherapy and surgery. 51 Therefore, benefits of the addition of radiation to perioperative chemotherapy have yet to be clarified.
Among Type III/IV gastric cancer, Type III and young Type IV had the same survival prognosis that was much better than elderly Type IV gastric cancer. 13 Elderly Type IV had the most dismal prognosis in resectable gastric cancer, which raises a question as to whether or not patients with this type of cancer should undergo surgery. 52 Elderly patients do not usually undergo standard therapy such as D2 gastrectomy, standard dose of postoperative S-1 therapy, and standard chemotherapy of cisplatin/S-1 (CS) for recurrent disease.
These therapeutic factors may affect the poor prognosis of elderly Type IV gastric cancer. However, importantly, peritoneal immunity declines with age. 53 If immunity is involved in the dismal prognosis of Type IV elderly gastric cancer, an immune checkpoint inhibitor such as nivolumab is a potential candidate to improve prognosis in elderly Type IV gastric cancer.
| Potentchemotherapyforhigh-risk gastriccancer
Japan Clinical Oncology Group considered neoadjuvant chemotherapy of CS to be a promising therapeutic strategy. In a phase II study (JCOG0210), CS combination chemotherapy provided relatively better survival with a 3-year survival rate of 24.5% and a median survival term of 17.3 months. 10 A phase III study (JCOG0501) comparing this preoperative chemotherapy followed by D2 surgery with surgery alone, both of which were followed by postoperative S-1 adjuvant chemotherapy for 1 year, finished patients' registration and provided a discouraging result with no additional benefit of neoadjuvant chemotherapy with CS. 11, 18 This result indicated that, at present, there is no indication for neoadjuvant therapy even in high-risk advanced gastric cancer.
A more potent chemotherapeutic regimen of docetaxel/cisplatin/S-1 (DCS) was developed in metastatic gastric cancer and achieved a response rate of 81%. 54 Actually, this result encouraged us to carry out conversion surgery for initially unresectable gastric cancer. 55 Regrettably, a JCOG1002 study investigating Of the patients undergoing conversion surgery, Type III or IV cancer accounted for 87%. 55 In the integrated analysis of these patients, Type IV cancer was selected as an independent prognostic factor (data not shown). The fact that Type IV cancer has a dismal prognosis and tends to recur at the peritoneum even after aggres- 
| CON CLUS IONS
The present review summarizes the association between macroscopic appearance as well as histological phenotypes to oncological outcomes. In type 0 gastric cancer, survival outcomes are so much better that the extent of cancer resection will become more and more limited to preserve the function of the stomach and maintain the QOL of patients. Indication for endoscopic resection would be expanded and partial resection using sentinel lymph node navigation would be applied to this type of cancer.
In stage II/III advanced gastric cancer, treatment strategy will be separately discussed between average-risk cancer and high-risk cancer. In average-risk cancer, adjuvant chemotherapy with DS in addition to adjuvant S-1 monotherapy will improve the survival outcomes of patients. In high-risk cancer, which is determined according to the gross appearance of the tumor, development of an effective neoadjuvant chemotherapeutic regimen is still awaited.
Average-risk gastric cancer is composed of Type I, Type II, small
Type III, and Type V and has heterogeneous molecular aberrations. 
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